Fmr LLC Buys 46,110 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Fmr LLC grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 2.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,988,389 shares of the biotechnology company’s stock after purchasing an additional 46,110 shares during the quarter. Fmr LLC owned about 0.96% of BioCryst Pharmaceuticals worth $15,112,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in BCRX. Deerfield Management Company L.P. Series C increased its stake in shares of BioCryst Pharmaceuticals by 62.9% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock worth $50,279,000 after acquiring an additional 3,140,804 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of BioCryst Pharmaceuticals by 528.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company’s stock worth $6,874,000 after acquiring an additional 935,132 shares in the last quarter. Fisher Asset Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after acquiring an additional 481,359 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of BioCryst Pharmaceuticals by 1,058.1% in the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after acquiring an additional 375,890 shares in the last quarter. Finally, Point72 Europe London LLP bought a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter worth about $1,654,000. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Up 2.6 %

Shares of NASDAQ BCRX opened at $7.93 on Wednesday. The firm’s 50-day moving average price is $7.60 and its 200-day moving average price is $7.37. The company has a market cap of $1.64 billion, a PE ratio of -13.00 and a beta of 1.79. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. The business’s revenue was up 35.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.19) EPS. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on BCRX shares. Needham & Company LLC reiterated a “buy” rating and issued a $14.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $15.60.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.